Psychopaths are most likely to live in these US states
The research analyzed data from 1.8 million people across 183 countries, including 144,000 in the U.S., linking personality traits to societal factors like poverty, inequality, and violence.
Researchers found that in societies where rules are broken and conditions are poor, individuals tend to prioritize self-interest, leading to higher 'Dark Factor' levels.
U.S. states such as Louisiana, Mississippi, Texas, Nevada and New York were identified with higher 'Dark Factor' levels, while Utah, Vermont, and Alaska showed lower levels.
The study suggests that personality is shaped by societal conditions, implying that reforms to reduce corruption and inequality could help prevent the development of negative personality traits.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
28 minutes ago
- Reuters
The race to launch first weight-loss pill
August 19 - Makers of weight-loss drugs are expected to rake in more than $150 billion in revenue by the early 2030s, thanks to the ever-growing popularity of Eli Lilly's (LLY.N), opens new tab Zepbound and Novo Nordisk's ( opens new tab Wegovy. The GLP-1 drugs sold by both companies are weekly injections, although several drugmakers are racing to develop an oral medicine or pill that might prove to be as effective as the injectables. Pills are easier to manufacture and could also avoid some of the supply issues that were initially seen with Novo and Lilly's drugs. Here are some companies developing oral obesity drugs in the hopes of making their mark in a lucrative market: Orforglipron, the company's once-daily oral non-peptide GLP-1 agonist, helped patients shed 12.4% of body weight over 72 weeks at the highest dose in a late-stage trial. Lilly plans to file for regulatory approval by the end of 2025 and is preparing for global submissions and manufacturing scale-up. Oral semaglutide, a pill version of the company's injectable GLP-1 active ingredient, demonstrated about 15% weight loss in a late-stage trial. The drug is currently under regulatory review, with a U.S. FDA decision expected in late 2025. Novo is also exploring next-generation oral combinations. Structure Therapeutics is developing GSBR-1290, a non-peptide oral GLP-1 agonist. Last year, the drug helped reduce weight by 6.2% on average at the end of 12 weeks in a mid-stage study. It is expected to report results from another mid-stage trial in the fourth quarter. The company, in partnership with Hansoh Pharma, is preparing to test HS-10535, an oral small-molecule GLP-1 agonist, in early-stage trials. The drug is currently being tested in lab studies. AstraZeneca and Eccogene are advancing ECC5004, a once-daily GLP-1 receptor agonist pill. Early stage trial showed a promising weight-loss signal and a favorable safety profile, with mid stage trials planned under AstraZeneca's lead. Roche, following its acquisition of Carmot Therapeutics, is working on CT-966, an oral GLP-1 agonist. CT-966 resulted in a placebo-adjusted average weight loss of 6.1% within four weeks in obese patients without diabetes in an early-stage trial last year. The company is developing an oral formulation of VK2735, which targets both GLP-1 and GIP hormones that regulate the body's metabolism. In a mid-stage study of 280 overweight adults with at least one obesity-related comorbidity, the pill achieved up to 12.2% mean weight loss over 13 weeks, compared with placebo. Pfizer was developing danuglipron, initially as a twice-daily oral GLP-1 agonist, but scrapped development after data from a mid-stage trial showed poor tolerability. A once-daily extended-release version was later tested in about 1,400 patients but liver safety concerns remained, dampening the company's plans to enter the obesity drug market.
The Independent
an hour ago
- The Independent
Diamonds could help detect cancer using groundbreaking new technique
Scientists have developed a diamond -based sensor that could make it easier for doctors to detect the spread of cancer. Researchers at the University of Warwick have created a handheld device that is designed to trace tiny magnetic particles injected into the body. The scientists said this offers a non-toxic alternative to radioactive tracers and dyes currently used in hospitals. Metastasis, when cancer cells spread from the original tumour to other parts of the body, is one of the most serious challenges in cancer treatment. Doctors often rely on tests to see whether the cancer has reached the lymph nodes – the areas of tissue that filter fluid in your body for harmful substances – which can guide decisions about surgery and further care. The findings, published in Physical Review Applied, describe how diamonds can be used to build a highly sensitive sensor capable of identifying the magnetic tracer fluid injected into a tumour. This fluid, made up of iron oxide nanoparticles, travels through the body alongside cancer cells, revealing whether they have reached the lymph nodes, the researchers said. Lead author Alex Newman, a PhD student in Warwick University's physics department, said the new tool could improve the way doctors find cancer in keyhole and endoscopic surgery. 'There is a real demand for versatile non-toxic means of finding cancer,' he said. 'For this new diamond-based sensor, we managed to get the size of the sensor head down to just 10 millimetres, which means it is the first diamond sensor to be able to detect magnetic tracer fluid while being small enough for endoscopic use and keyhole surgery.' Mr Newman added that the device was extremely sensitive, capable of detecting just one hundredth of the typical dose of magnetic tracer fluid. The design uses a diamond measuring only half a cubic millimetre alongside a small permanent magnet, the scientists said They added that this compact structure means there is no need for bulky electronics, allowing the sensor to be used by hand in operating rooms. Professor Gavin Morley, who leads the research group, said the breakthrough was possible thanks to nitrogen vacancy centres inside the diamond. 'These allow the diamond to detect very small changes in the magnetic field and give the diamonds a lovely pink colour,' he said. He added that the technology could also have uses beyond medicine, including in spacecraft and fusion power. Current techniques for tracing cancer cells rely on radioactive tracers, which not all hospitals can access, or blue dyes, which trigger allergic reactions in some patients, the researchers said. Clinicians involved in this new project believe the new diamond sensor could help avoid these complications. Stuart Robertson, a consultant breast cancer surgeon at University Hospitals Coventry and Warwickshire, said he was already using magnetic localisation in his work. He added that it offers more advantages over traditional techniques. Researchers say the device could eventually be applied to various cancers, including lung, liver, colorectal and oesophageal tumours.
Reuters
an hour ago
- Reuters
Viking Therapeutics' oral pill helps up to 12.2% weight-loss in mid-stage study
Aug 19 (Reuters) - Viking Therapeutics (VKTX.O), opens new tab said on Tuesday its experimental weight-loss pill helped people with obesity lose up to 12.2% of their body weight over 13 weeks in a keenly-watched mid-stage study. Shares of the company slumped 30% in premarket trading after the company reported that, overall, 28% of people on the drug discontinued it, compared with 18% on placebo. Oral drugs are expected to take a significant share of the projected $150 billion weight-loss market, driven by their ease of use compared with injections such as Wegovy from Novo Nordisk ( opens new tab and Zepbound from Eli Lilly (LLY.N), opens new tab. Viking's experimental oral pill is in a tight race with rival treatments being developed by the deeper-pocketed Novo and Lilly. Analysts ahead of the results had expected weight loss in the range of 10% to 15% on average and greater than the 8.2% seen in a small early-stage trial. The study enrolled 280 overweight adults who had at least one comorbidity related to the disease.
